Liom (formerly Spiden) is developing a wristband that measures blood glucose non-invasively using Raman spectroscopy. The EUR 13.9 million Series A extension brings the Series A to CHF 38 million and will fund product development ahead of a 2028 launch.
- Announced on
- Round
- Series A
- Amount
- EUR 13.9 M
- Location
- Pfäffikon, canton of Schwyz
- Sector
- Health & medtech
Investors
- Red Bull Ventures
- Marc Maurer
- Melih Odemis
- Alejo Costa Ribalta
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic